Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Equity Average (2016 - 2025)

Historic Equity Average for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $7.4 million.

  • China Pharma Holdings' Equity Average rose 601.98% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 601.98%. This contributed to the annual value of $7.6 million for FY2024, which is 2944.25% up from last year.
  • China Pharma Holdings' Equity Average amounted to $7.4 million in Q3 2025, which was up 601.98% from $6.7 million recorded in Q2 2025.
  • China Pharma Holdings' Equity Average's 5-year high stood at $7.9 million during Q1 2024, with a 5-year trough of $3.4 million in Q3 2022.
  • In the last 5 years, China Pharma Holdings' Equity Average had a median value of $6.7 million in 2025 and averaged $6.2 million.
  • As far as peak fluctuations go, China Pharma Holdings' Equity Average plummeted by 4873.01% in 2022, and later soared by 9039.5% in 2023.
  • China Pharma Holdings' Equity Average (Quarter) stood at $6.4 million in 2021, then tumbled by 44.65% to $3.6 million in 2022, then surged by 90.39% to $6.8 million in 2023, then increased by 5.24% to $7.1 million in 2024, then grew by 3.5% to $7.4 million in 2025.
  • Its last three reported values are $7.4 million in Q3 2025, $6.7 million for Q2 2025, and $7.4 million during Q1 2025.